This market research report on the erectile dysfunction market offers analysis on market size and forecast, market share, industry trends, growth drivers, and vendor analysis. The study also includes insights on segmentation by therapy type (drug therapies and device therapies) and geography (APAC, Europe, Latin America, MEA, and North America).
Increasing disease awareness, growing patient willingness to seek medical assistance for disease management, and the increasing presence of favorable guidelines are driving the growth of the erectile dysfunction market. The three most popular erectile dysfunction drugs that are available in the market are ED oral drugs, Viagra, Cialis, and Levitra. The global erectile dysfunction market is also witnessing a rising demand for low-cost generic drugs, especially in the APAC countries such as Indian and China. The US and Europe are the main revenue contributors in the global erectile dysfunction market. The growing number of chronic medical conditions such as diabetes, hypertension, dyslipidemia, and coronary heart disease across the globe is also increasing the number of erectile dysfunction patients and boosting the demand for therapeutics in the global market. The increasing investments in R&D for the development of new drugs and clinical trials will augment the growth of the erectile dysfunction market.
The growing awareness of male sexual health conditions and the increasing healthcare spending for sexual wellness, especially in the APAC region will propel the development of the erectile dysfunction market. The introduction of innovative drug therapy will have a positive impact on the growth of the erectile dysfunction market. The erectile dysfunction market is expected to generate revenue of $4.25 billion during the forecast period.
Global Erectile Dysfunction Market Size by Revenue
Increase in strategic agreements and consolidations among the leading vendors to expand their services or product portfolios is likely to contribute to the growth of the global erectile dysfunction market. Mergers and acquisitions will allow players to gain competitive advantage with a wide product portfolio and vast geographical reach, thereby driving the growth and profitability of vendors in the erectile dysfunction market. These strategic consolidations and mergers will help prominent companies to expand their businesses in emerging markets and widen their distribution networks to attract a large consumer base. For instance, a licensing agreement between A. Menarini Asia-Pacific and Mitsubishi Tanabe Pharma was signed to commercialize and promote avanafil in China, Hong Kong, Taiwan, Macao, the Philippines, Singapore, Indonesia, Malaysia, Thailand, and Vietnam.
This market research report includes a detailed segmentation of the market by therapy and geography.
Segmentation of global Erectile Dysfunction Market by Therapy Type
Erectile Dysfunction Market – By Therapy Type
Drugs therapy type to dominate the erectile dysfunction market during the forecast period
The erectile dysfunction market by therapy type is classified into drugs and devices. The drugs therapy segment dominated the erectile dysfunction market, accounting for close to 89% of the total market share in 2017 and is expected to generate revenue of about $3,487.41 million during the forecast period. Preferability for needle-free penile injection kits and increase in disease awareness will fuel the growth of this drug segment in the erectile dysfunction market. The market for other drug therapy types, topical agents, intraurethral suppositories, and intracavernosal injections is expected to grow at a moderate pace over the next few years. The erectile dysfunction market will also observe a negative growth due to the patent expiration of generic versions of key oral drugs Viagra, Cialis, and Levitra during the forecast period.
Erectile Dysfunction Market – By Geography
North America to occupy the largest market share in the erectile dysfunction market during the forecast period
The geographical segment in the erectile dysfunction market is divided into APAC, Europe, Latin America, MEA, and North America. North America dominated the global erectile dysfunction market, occupying more than 43% of the total market share in 2017 and is expected to generate the revenue of $1,832.82 million by 2023. Factors such as better access to ED treatments and reimbursement coverage for high post penile implant surgeries is fueling the growth of the erectile dysfunction market in North America. The US accounts for more than 90% of the total market share in the erectile dysfunction market in North America. The high uptake and access to both prescription and OTC devices in North America is attributing the revenue of the erectile dysfunction market in this region. Moreover, increasing penile implantation surgical procedures, growing e-commerce sales of penile erection devices, and rising preference for advanced non-invasive devices will have a positive impact on the growth of the erectile dysfunction market in North America.
Key Countries Profiled in the report are
Key Vendor Analysis
The erectile dysfunction market is oligopolistic, as a limited number of major players occupies the predominant market share. A minority of the market share has occupied by a surfeit of specialty and generic drug companies. The strategic initiatives adopted by the leading and other prominent companies will intensify the competition in the erectile dysfunction market during the forecast period. The leading companies are focusing on leveraging their strengths to diversify their product portfolios and increase their global market presence. The entry of new players and the introduction of innovative therapeutics will increase the level of competition in the global erectile dysfunction market during the forecast period.
The major vendors in the global market are:
Other prominent vendors include Apricus Biosciences, Inc, Endo International plc, Futura Medical, Premedon, Teva Pharmaceutical Industries Limited (Teva), Zephyr Surgical Implants (ZSI), Augusta Medical Systems LLC (Augusta Medical), Post-T-Vac Medical, Bonro Medical, Cristalia Produtos Quimicos Farmaceuticos Ltd, and SK Chemicals.
Get the updated report free if published within 100 days of purchase
Free datasheet worth $1500 with team and corporate license.
10% free customization. Speak to our analyst